Addex Therapeutics announces NTX-253 phase 1 completion
- Completed phase 1 studies for NTX-253 in schizophrenia
- Neurosterix, 20% owned by Addex, advances to phase 2
- NTX-253 is a muscarinic M4 receptor PAM
Every EDGAR filing for Addex Therapeutics Ltd. (ADXN), newest first, with AI summaries and stories.
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Lenaic Nathanael Teyssedou, insider filing for ADXN
Lenaic Nathanael Teyssedou, reporting
Ownership stake disclosure by Timothy Mark Dyer (amended)
Timothy Mark Dyer, filed by
Ownership stake disclosure by Timothy Mark Dyer (amended)
Timothy Mark Dyer, filed by
Roger Mills, new insider at ADXN
Roger Mills, reporting
Timothy Mark Dyer, new insider at ADXN
Timothy Mark Dyer, reporting